On August 1, 2018 Cell Medica (or ‘the Company’), a leader in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, reported that it has appointed Chris Nowers as Chief Executive Officer and Executive Director (Press release, Cell Medica, AUG 1, 2018, https://cellmedica.com/press-releases/cell-medica-appoints-new-ceo-drive-car-tcr-clinical-development-commercialisation/ [SID1234528417]). His appointment follows founder Gregg Sando’s decision to step down as Chief Executive Officer and Director of the Company and is effective 1 August 2018.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr Nowers joins Cell Medica from the cancer immunotherapy company Kite Pharma (Kite), where he was Head of Europe and responsible for the full commercialisation of the CAR-T therapy axicabtagene ciloleucel. At Kite he built the European organisation from the ground up and, post the $12 Bn acquisition by Gilead Sciences in 2017, was subsequently responsible for the continued expansion of the Kite organisation within the Europe, Middle East and Africa structure. Previous to his role at Kite, he has had a career spanning more than 25 years in the biopharma industry. He has held a number of senior leadership roles that included CEO of Avantogen Oncology, General Management roles at Amgen, and senior global and regional commercial leadership roles at Bristol-Myers Squibb (BMS). Whilst at BMS, he built and led teams that delivered the successful launches of the checkpoint inhibitors ipilimumab and nivolumab.
Mr Sando, a pioneer in the field of cellular immunotherapy, established Cell Medica in 2006 and led the company’s transition into the CAR-T technology space. The upcoming initiation of clinical trials investigating CAR-modified cell therapy products will mark an important new chapter in the Company’s development. He will assist over the coming months in transitioning to new senior leadership.
Annalisa Jenkins, Chair of Cell Medica, commented:
"We would like to thank Gregg for his vision and commitment over the last 12 years, which has led to Cell Medica becoming a leader in cellular immunotherapy for cancer. He has built an experienced international team with the capability to build on existing research partnerships and develop the internal pipeline to maximise shareholder value.
"We are pleased to welcome Chris as Cell Medica’s new CEO. His experience in the commercialisation of oncology programmes is an excellent fit for the Company’s ambitions as we progress towards realising our goals of delivering compelling new cellular immunotherapies for the treatment of cancer patients."
Gregg Sando commented:
"It has been a great experience founding Cell Medica and leading a team of dedicated colleagues and research collaborators who have been working together to transform the treatment of cancer through cell-based immunotherapy. The Company is well positioned for an exciting future and it is now time to transition to new leadership who will take our products and technology through clinical development and commercialisation. My thanks and appreciation to the extended Cell Medica team and partners, past and present."
Chris Nowers commented:
"Cell Medica has an exciting array of technologies that will help unlock the potential of personalised cellular immunotherapies for both blood cancers and solid tumours. I look forward to working with the Company’s talented executive and scientific teams to take these promising treatments to patients through clinical development."